Trials / Completed
CompletedNCT04188665
Using MASL to Combat Oral Cancer
Using Maackia Amurensis Seed Lectin to Target the Podoplanin Receptor as a Functionally Relevant Biomarker to Inhibit the Growth of Oral Squamous Cell Carcinoma and Precancerous Lesions
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Rowan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MASL | Patients treated with MASL lozenge |
| OTHER | Placebo | Patients treated with placebo lozenge |
Timeline
- Start date
- 2021-01-29
- Primary completion
- 2024-12-31
- Completion
- 2025-05-15
- First posted
- 2019-12-06
- Last updated
- 2026-03-20
- Results posted
- 2026-03-20
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04188665. Inclusion in this directory is not an endorsement.